Ovoca Bio PLC
LSE:OVB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.55
1.92
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ovoca Bio PLC
Ovoca Bio PLC
Cash & Cash Equivalents
Ovoca Bio PLC
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ovoca Bio PLC
LSE:OVB
|
Cash & Cash Equivalents
€2.9m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-11%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Cash & Cash Equivalents
$1.5B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
30%
|
CAGR 10-Years
5%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Cash & Cash Equivalents
$2.2B
|
CAGR 3-Years
60%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Cash & Cash Equivalents
$28.6m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
2%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Cash & Cash Equivalents
$78.4m
|
CAGR 3-Years
137%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Cash & Cash Equivalents
€54.6m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
7%
|
|
Ovoca Bio PLC
Glance View
Ovoca Bio Plc is a clinical-stage biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The firm is engaged in identifying and developing therapeutics targeting the treatment of female sexual dysfunction. The Company’s product BP101 is a synthetic peptide, administered through a nasal spray that is being developed for the treatment of female sexual dysfunction-hypoactive sexual desire disorder (HSDD). The Company’s subsidiaries include Silver Star Ltd, Bulun LLC, Magsel LLC, IVIX LLC and OVB (Australia) Pty Ltd. The firm operates in Ireland, the United Kingdom (UK) and Russia.
See Also
What is Ovoca Bio PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.9m
EUR
Based on the financial report for Jun 30, 2024, Ovoca Bio PLC's Cash & Cash Equivalents amounts to 2.9m EUR.
What is Ovoca Bio PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-11%
Over the last year, the Cash & Cash Equivalents growth was 4%. The average annual Cash & Cash Equivalents growth rates for Ovoca Bio PLC have been -32% over the past three years , 2% over the past five years , and -11% over the past ten years .
You don't have any saved screeners yet
